Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals

Age could guide use of PSA testing and MRI prostate cancer screening in men with a germline BRCA1/2 mutation

Metastatic hormone receptor-positive, HER2-negative breast cancer patients may respond to sacituzumab govitecan

Circulating tumour DNA testing can help identify breast cancer mutations with targetable therapies

A high tumour mutational burden may help identify patients with previously treated cancer who are likely to benefit from pembrolizumab therapy

Cancer patients using immune checkpoint inhibitor therapy may be less likely to be diagnosed with a second primary cancer than those given other types of treatment

Further evidence that androgen deprivation therapy should be offered only to patients with unfavourable intermediate-risk prostate cancer

Progression-free survival can be used to estimate overall survival in studies assessing immune checkpoint inhibitor agents